尼达尼布治疗特发性肺纤维化的疗效和安全性.pdfVIP

Thenewengland

journalofmedicine

establishedin1812may29,2014vol.370no.22

EfficacyandSafetyofNintedanibinIdiopathic

PulmonaryFibrosis

LucaRicheldi,M.D.,Ph.D.,RolandM.duBois,M.D.,GaneshRaghu,M.D.,ArataAzuma,M.D.,Ph.D.,

KevinK.Brown,M.D.,UlrichCostabel,M.D.,VincentCottin,M.D.,Ph.D.,KevinR.Flaherty,M.D.,

DavidM.Hansell,M.D.,YoshikazuInoue,M.D.,Ph.D.,DongSoonKim,M.D.,MartinKolb,M.D.,Ph.D.,

AndrewG.Nicholson,D.M.,PaulW.Noble,M.D.,MoisésSelman,M.D.,HiroyukiTaniguchi,M.D.,Ph.D.,

MichèleBrun,M.Sc.,FlorenceLeMaulf,M.Sc.,MannaïgGirard,M.Sc.,SusanneStowasser,M.D.,

RozsaSchlenker-Herceg,M.D.,BerndDisse,M.D.,Ph.D.,andHaroldR.Collard,M.D.,

fortheINPULSISTrialInvestigators*

ABSTRACT

Background

Nintedanib(formerlyknownasBIBF1120)isanintracellularinhibitorthattargetsTheauthors’affiliationsarelistedinthe

multipletyrosinekinases.Aphase2trialsuggestedthattreatmentwith150mgofAppendix.Addressreprintrequeststo

Dr.RicheldiattheNationalInstitutefor

nintedanibtwicedailyreducedlung-functiondeclineandacuteexacerbationsinHealthResearch,SouthamptonRespira-

patientswithidiopathicpulmonaryfibrosis.toryBiomedicalResearchUnit,Mailpoint